GLP1R and type 2 diabetes mellitus: The new results of sacubitril/valsartan trial and GLP-1 RA and SGLT2i studies will likely shape the future management of T2D in CV disease, and upcoming society guidelines will likely be even more closely intertwined and multidisciplinary in nature.